Keywords
Diuretics
Oxygen Inhalation Therapy
Heart Failure
Oxygen Inhalation Therapy
Heart Failure
How to Cite
Uhia Villero, A. M., Marín Castaño, K. D. C., Rodríguez Criado, C. A., & Duarte Duarte, W. (2013). Management of acute heart failure in the emergency department: drug therapy approach. Médicas UIS, 26(1). Retrieved from https://revistas.uis.edu.co/index.php/revistamedicasuis/article/view/3593
Abstract
According to Colombian society of cardiology, heart failure is a syndrome characterized by high mortality, frequent hospitalization and poor quality of life, particularly in the context of generating multiple comorbidities, overall, a high cost of care, thus pharmacological measures were designed for the management of this condition in the emergency department, as a fundamental pillar for medical staff when faced with a patient with an acute crisis. A review of the indications of different therapies, such as the use of oxygen therapy, loop diuretics, vasodilators, ionotropes, vasopressors, as initial therapy, and others such as opioids, beta-blockers. The main objective of this paper is to review literature, mainly based on articles and updated guidelines, gather information about the ideal management, this identifying the groups of drugs of choice, precautions and contraindications of these. (MÉD.UIS.2013;26(1):69-79).
References
1. Accini M.José Luis. Atehortúa López Luis. Castillo B. Gilberto. De la Rosa Echavez Gisela. Dueñas Carmelo. Senior Sánchez Juan M., FACP, et al. Guías Colombianas de cardiología tratamiento de la falla cardíaca aguda, Sociedad Colombiana de Cardiología y Cirugía Cardiovascular - Asociación Colombiana de Medicina Crítica y Cuidado Intensivo Medellín, Colombia. Febrero 2011; Volumen 18 Suplemento.
2. John J. V. McMurray. Stamatis Adamopoulos. Stefan D. Anker. Angelo Auricchio. Michael Bohm. Kenneth Dickstein.et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 - The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Pag 6, 39-41.
3. Donald Lloyd-Jones, MD, ScM, FAHA; Robert J. Adams, MD, FAHA; Todd M. Brown, MD; Mercedes Carnethon, PhD, FAHA; Shifan Dai, MD, PhD; Giovanni De Simone, MD; et al. Heart Disease and Stroke Statistics—2010 Update - A Report From the American Heart Association.
4. Ramachandran S Vasan, MD, DM, FACC, Peter WF Wilson, Epidemiology and causes of heart failure, Literature review Sep 2012, Uptodate.
5. Ospina Serrano Aylen Vanessa, Gamarra Hernández Germán, Características clínicas y epidemiológicas de la insuficiencia cardiaca en el Hospital Universitario Ramón González Valencia de Bucaramanga, Colombia. Salud Uis. 2004;36(3).
6. Sociedad Argentina de Cardiología. Área de Normatizaciones y Consensos. Consejo de Insuficiencia Cardíaca. Consenso de Diagnóstico y Tratamiento de la Insuficiencia Cardíaca Crónica. Rev Argent Cardiol. 2010;78: 166-81.
7. Gage J, Rutman H, Lucido D, LeJemtel TH. Additive effects of dobutamine and amrinone on myocardial contractility and ventricular performance in patients with severe heart failure. Circulation. 1986;74:367.
8. Mager G, Klocke RK, Kux A, et al. Phosphodiesterase III inhibition or adrenoreceptor stimulation: milrinone as an alternative to dobutamine in the treatment of severe heart failure. Am Heart J. 1991;121:1974.
9. Hunt SA, Abraham WT, Chin MH, et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation. 2009;119:e391.
10. Wilson S Colucci, MD, Stephen S Gottlieb, MD, Susan B Yeon, MD, JD, FACC, Inotropic agents in heart failure due to systolic dysfunction. DIC 15, 2009
11. Alexandre Mebazaa,1,* Markku S. Nieminen,2 Gerasimos S. Filippatos,3 John G. Cleland,4 Jeffrey E. Salon,5 Roopal Thakkar,5 Robert J. Padley,5 Bidan Huang,5 and Alain Cohen-Solal6 Levosimendan vs. dobutamine: outcomes for acute heart failure patients on β-blockers in SURVIVE, 29 enero 2009.
12. Heart Failure Society of America, Lindenfeld J, Albert NM, et al. HFSA 2010 Comprehensive Heart Failure Practice Guideline. J Card Fail 2010; 16:e1
13. Palmer RF, Lasseter KC. Drug therapy. Sodium nitroprusside. N Engl J Med 1975.
14. Gregory JS, Bonfiglio MF, Dasta JF, et al. Experience with phenylephrine as a component of the pharmacologic support of septic shock. Crit Care Med 1991; 19:1395.
15. Practice parameters for hemodynamic support of sepsis in adult patients in sepsis. Task Force of the American College of Critical Care Medicine, Society of Critical Care Medicine. Crit Care Med 1999.
16. Nalaka Gooneratne, MD, MSCE, Scott Manaker, MD, PhD, Use of vasopressors and inotropes may 4, 2012.
17. Goldb erg LI. Dopamine--clinical uses of an endogenous catecholamine. N Engl J Med. 1974;291:707.
18. Dasta JF, Kirby MG. Pharmacology and therapeutic use of low-dose dopamine. Pharmacotherapy 1986; :304.
19. Löllgen H, Drexler H. Use of inotropes in the critical care setting. Crit Care Med. 1990;18:S56.
20. Steel, A, Bihari, D. Choice of catecholamine: does it matter?. Curr Opin Crit Care. 2000;6:347
21. Pérez LLorens, Òscar miró, Francisco Javier Martín Sánchez, pablo herrero puente, Javier Jacob Rodríguez, Víctor Gil, Rafael Perello, Alfonso Aguirre, Amparo Valero, en representación de los miembros del grupo ICA-SEMES. Manejo de la insuficiencia cardiaca aguda en los servicios de urgencias, emergencias y unidades adscritas. Documento de consenso del grupo de insuficiencia cardiaca aguda de la sociedad española de medicina de urgencias y emergencias (ICA-SEMES).Madrid: Febrero 2011; P133. Emergencias. 2011;23: 119-139.
22. Flather MD, Shibata MC, Coats AJ, Van Veldhuisen DJ, Parkhomenko A, Borbola J, et al. Randomized trial to determine the effect of Novibolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J. 2005; 26: 215- 25. PubMed.
23. Mineralocorticoid receptor antagonism: therapeutic potential in acute heart failure syndromesEur Heart J (2011) 32(21): 2626-2633 first published online June 14, 2011 European heart journal.
2. John J. V. McMurray. Stamatis Adamopoulos. Stefan D. Anker. Angelo Auricchio. Michael Bohm. Kenneth Dickstein.et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 - The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Pag 6, 39-41.
3. Donald Lloyd-Jones, MD, ScM, FAHA; Robert J. Adams, MD, FAHA; Todd M. Brown, MD; Mercedes Carnethon, PhD, FAHA; Shifan Dai, MD, PhD; Giovanni De Simone, MD; et al. Heart Disease and Stroke Statistics—2010 Update - A Report From the American Heart Association.
4. Ramachandran S Vasan, MD, DM, FACC, Peter WF Wilson, Epidemiology and causes of heart failure, Literature review Sep 2012, Uptodate.
5. Ospina Serrano Aylen Vanessa, Gamarra Hernández Germán, Características clínicas y epidemiológicas de la insuficiencia cardiaca en el Hospital Universitario Ramón González Valencia de Bucaramanga, Colombia. Salud Uis. 2004;36(3).
6. Sociedad Argentina de Cardiología. Área de Normatizaciones y Consensos. Consejo de Insuficiencia Cardíaca. Consenso de Diagnóstico y Tratamiento de la Insuficiencia Cardíaca Crónica. Rev Argent Cardiol. 2010;78: 166-81.
7. Gage J, Rutman H, Lucido D, LeJemtel TH. Additive effects of dobutamine and amrinone on myocardial contractility and ventricular performance in patients with severe heart failure. Circulation. 1986;74:367.
8. Mager G, Klocke RK, Kux A, et al. Phosphodiesterase III inhibition or adrenoreceptor stimulation: milrinone as an alternative to dobutamine in the treatment of severe heart failure. Am Heart J. 1991;121:1974.
9. Hunt SA, Abraham WT, Chin MH, et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation. 2009;119:e391.
10. Wilson S Colucci, MD, Stephen S Gottlieb, MD, Susan B Yeon, MD, JD, FACC, Inotropic agents in heart failure due to systolic dysfunction. DIC 15, 2009
11. Alexandre Mebazaa,1,* Markku S. Nieminen,2 Gerasimos S. Filippatos,3 John G. Cleland,4 Jeffrey E. Salon,5 Roopal Thakkar,5 Robert J. Padley,5 Bidan Huang,5 and Alain Cohen-Solal6 Levosimendan vs. dobutamine: outcomes for acute heart failure patients on β-blockers in SURVIVE, 29 enero 2009.
12. Heart Failure Society of America, Lindenfeld J, Albert NM, et al. HFSA 2010 Comprehensive Heart Failure Practice Guideline. J Card Fail 2010; 16:e1
13. Palmer RF, Lasseter KC. Drug therapy. Sodium nitroprusside. N Engl J Med 1975.
14. Gregory JS, Bonfiglio MF, Dasta JF, et al. Experience with phenylephrine as a component of the pharmacologic support of septic shock. Crit Care Med 1991; 19:1395.
15. Practice parameters for hemodynamic support of sepsis in adult patients in sepsis. Task Force of the American College of Critical Care Medicine, Society of Critical Care Medicine. Crit Care Med 1999.
16. Nalaka Gooneratne, MD, MSCE, Scott Manaker, MD, PhD, Use of vasopressors and inotropes may 4, 2012.
17. Goldb erg LI. Dopamine--clinical uses of an endogenous catecholamine. N Engl J Med. 1974;291:707.
18. Dasta JF, Kirby MG. Pharmacology and therapeutic use of low-dose dopamine. Pharmacotherapy 1986; :304.
19. Löllgen H, Drexler H. Use of inotropes in the critical care setting. Crit Care Med. 1990;18:S56.
20. Steel, A, Bihari, D. Choice of catecholamine: does it matter?. Curr Opin Crit Care. 2000;6:347
21. Pérez LLorens, Òscar miró, Francisco Javier Martín Sánchez, pablo herrero puente, Javier Jacob Rodríguez, Víctor Gil, Rafael Perello, Alfonso Aguirre, Amparo Valero, en representación de los miembros del grupo ICA-SEMES. Manejo de la insuficiencia cardiaca aguda en los servicios de urgencias, emergencias y unidades adscritas. Documento de consenso del grupo de insuficiencia cardiaca aguda de la sociedad española de medicina de urgencias y emergencias (ICA-SEMES).Madrid: Febrero 2011; P133. Emergencias. 2011;23: 119-139.
22. Flather MD, Shibata MC, Coats AJ, Van Veldhuisen DJ, Parkhomenko A, Borbola J, et al. Randomized trial to determine the effect of Novibolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J. 2005; 26: 215- 25. PubMed.
23. Mineralocorticoid receptor antagonism: therapeutic potential in acute heart failure syndromesEur Heart J (2011) 32(21): 2626-2633 first published online June 14, 2011 European heart journal.
Downloads
Download data is not yet available.